Author’s response to reviews

Title: The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release mediated apoptosis in renal cell carcinoma cells

Authors:

Ki Cheong Park (ggiru95@yuhs.ac)
Hye Ji Choi (hj423@yuhs.ac)
A Ra Jo (ara0315@yuhs.ac)
Jun Hyeok Heo (ANOHINI@yuhs.ac)
Hye Young Kim (hywhitecat@yuhs.ac)
Seung Won Kim (SWKIM21C@yuhs.ac)
Ho Jeong Kwon (kwonhj@yonsei.ac.kr)
Sung Joon Hong (sjhong346@yuhs.ac)
Kyung Seok Han (khan@yuhs.ac)

Version: 4
Date: 4 October 2014

Author’s response to reviews: see over
Dear Editor,

I would like to submit a paper titled “The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release mediated apoptosis in renal cell carcinoma cells” to BMC Cancer.

Preclinical models have revealed that histone gene modifiers and epigenetic alterations play important roles in renal cell carcinoma (RCC) tumorigenesis. we demonstrate the apoptosis-inducing activity of a novel HDAC inhibitor, N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA) and HNHA has more potent anti-tumor activity than established HDAC inhibitors and its activities are mediated by caspase-dependent and cytochrome-c-mediated apoptosis in RCC. We think that our data suggest that HNHA may offer a new therapeutic approach to RCC could be of much help in the novel therapeutic strategy for advanced renal cell carcinoma.

All authors including myself have seen and approved this manuscript and this manuscript has not been published in any journal and is not under consideration for publication elsewhere.

I hope you will consider this paper as suitable for publication in your journal.

I am looking forward to your reply.

Thank you in advance.

Sincerely,

Kyung Seok Han